Get the Stockscreener App
5.14
0.00%
0.00
Third Harmonic Bio Inc stock is traded at $5.14, with a volume of 167.76K.
It is up +0.00% in the last 24 hours and up +46.02% over the past month.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
See More
Previous Close:
$5.14
Open:
$5.12
24h Volume:
167.76K
Relative Volume:
0.20
Market Cap:
$232.29M
Revenue:
-
Net Income/Loss:
$-32.74M
P/E Ratio:
-6.2683
EPS:
-0.82
Net Cash Flow:
$-24.89M
1W Performance:
-0.39%
1M Performance:
+46.02%
6M Performance:
-60.91%
1Y Performance:
-50.86%
1-Day Range:
$5.12
$5.15
1-Week Range:
$5.08
$5.20
52-Week Range:
$3.18
$16.94
Third Harmonic Bio Inc Stock (THRD) Company Profile
Name
Third Harmonic Bio Inc
Sector
Industry
Phone
(209) 727-2457
Address
1700 MONTGOMERY STREET, SAN FRANCISCO
Compare THRD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
THRD
Third Harmonic Bio Inc
|
5.14 | 232.29M | 0 | -32.74M | -24.89M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Third Harmonic Bio Inc Stock (THRD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-25 | Downgrade | Stifel | Buy → Hold |
| Feb-12-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-11-25 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-09-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-18-24 | Initiated | Stifel | Buy |
| Jun-07-24 | Initiated | Raymond James | Outperform |
| Dec-16-22 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-22 | Initiated | Cowen | Outperform |
| Oct-10-22 | Initiated | Jefferies | Buy |
| Oct-10-22 | Initiated | Morgan Stanley | Overweight |
View All
Third Harmonic Bio Inc Stock (THRD) Latest News
Fierce Biotech Layoff Tracker 2025: Caribou cuts 32% of staff; Mural lays off 90% - Fierce Biotech
Third Harmonic Bio CSO steps down, enters separation agreement - Investing.com Australia
Third Harmonic Bio’s CSO Christopher Dinsmore Steps Down - MSN
Third Harmonic Bio CSO steps down, enters separation agreement By Investing.com - Investing.com South Africa
New fund Alis offers struggling biotechs an off-ramp: Finance Report - BioCentury
Finance Watch: Investors Push ESSA Pharma, Elevation Oncology To Wind Down - insights.citeline.com
SF biotech company, once worth nearly $1 billion, plans to shut down - SFGATE
Biotech Alert: Searches spiking for these stocks today - TipRanks
Third Harmonic Bio (THRD) Plans Liquidation; Significant Search Surge in Biotech Sector | ARTL Stock News - GuruFocus
Third Harmonic Bio (THRD) Seeks Stockholder Approval for Liquida - GuruFocus
Third Harmonic Bio plans to liquidate the company, sell urticaria treatment - MSN
Third Harmonic Bio, Inc. Liquidation and Shareholder Distribution: Analyst Maintains Hold Rating Amid Strategic Uncertainties - TipRanks
Third Harmonic's shutdown, Coherus and Xoma drug sales connectedBizwomen - The Business Journals
Third Harmonic Bio leaps as it reveals liquidation plan - The Pharma Letter
Big moves by small biotechs signal potential shift for investorsSan Francisco Business Times - The Business Journals
Top 3 Health Care Stocks You May Want To Dump This Quarter - Benzinga
Third Harmonic Bio Announces Liquidation Plan: Stock Skyrockets 39% Pre-Market, But Retail’s Shattered - MSN
Third Harmonic Bio plans liquidation and asset sale By Investing.com - Investing.com South Africa
$26bn Brighton Jones hires new CFO - Citywire
Third Harmonic Bio, Apple, Dell And Other Big Stocks Moving Higher In Monday's Pre-Market Session (CORRECTED) - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Third Harmonic outlines plans for dissolution - BioPharma Dive
Third Harmonic Bio sees initial distribution of $5.13-$5.33 from liquidation - TipRanks
Third Harmonic Bio stock holds as liquidation plan unveiled By Investing.com - Investing.com Canada
Third Harmonic Bio Stock Is Up 40% Monday: What's Happening?Third Harmonic Bio (NASDAQ:THRD) - Benzinga
Third Harmonic Announces Liquidation And Cash Return, Stock Jumps - Nasdaq
Third Harmonic to shutter; Future Pak once again targets Theratechnologies - Endpoints News
THRD’s Ambitious Moves: From Trials to Strategies? - timothysykes.com
Third Harmonic Bio Plans Liquidation With Lucrative Payouts - Finimize
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Third Harmonic Bio announces plan of liquidation and dissolution - TipRanks
Third Harmonic Seeks to Liquidate, Dissolve Company - marketscreener.com
Third Harmonic Bio Announces Plan Of Liquidation And Dissolution - marketscreener.com
Third Harmonic Bio Announces Plan of Liquidation and Dissolution - The Manila Times
Third Harmonic Bio plans liquidation and asset sale - Investing.com Australia
Third Harmonic Bio to Return $255M to Shareholders in Major Cash Distribution - Stock Titan
Layoff Tracker: Opthea Slashes 65% of Staff, Pfizer Cuts 56 - BioSpace
Third Harmonic stock rating cut by Raymond James - MSN
Third Harmonic Bio initiates process to identify opportunities to maximize value - TipRanks
Hold Rating for Third Harmonic Bio, Inc. Amid Strategic Exploration and Cautious Development Approach - TipRanks
Stifel Downgrades Third Harmonic Bio (THRD) - MSN
Stifel Nicolaus Downgrades Third Harmonic Bio to Neutral From Buy, Adjusts Price Target to $5 From $23 - MarketScreener
Third Harmonic Bio Reports 2024 Financial Results and Strategic Plans - TipRanks
Third Harmonic Bio reports FY24 EPS ($1.09) vs. (78c) last year - TipRanks
Stifel cuts Third Harmonic stock rating to hold, slashes target to $5 - Investing.com
Third Harmonic Bio Inc Stock (THRD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
36.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):